245 related articles for article (PubMed ID: 19255962)
1. [Erythropoiesis-stimulating agents in chronic kidney disease: which route of administration?].
Borrelli S; Baldanza D; Scigliano R; Catapano F; Grimaldi M; Calabria M; Zamboli P; Minutolo R; De Nicola L; Conte G
G Ital Nefrol; 2009; 26(1):31-7. PubMed ID: 19255962
[TBL] [Abstract][Full Text] [Related]
2. Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data.
Carrera F; Disney A; Molina M
Nephrol Dial Transplant; 2007 Jun; 22 Suppl 4():iv19-iv30. PubMed ID: 17526546
[TBL] [Abstract][Full Text] [Related]
3. Optimizing anaemia management with subcutaneous administration of epoetin.
Besarab A
Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi10-5. PubMed ID: 15958820
[TBL] [Abstract][Full Text] [Related]
4. Is it time to reconsider subcutaneous administration of epoetin?
Patel TV; Robinson K; Singh AK
Nephrol News Issues; 2007 Oct; 21(11):57, 59, 63-4 passim. PubMed ID: 17970510
[TBL] [Abstract][Full Text] [Related]
5. Triumph and tragedy: anemia management in chronic kidney disease.
Novak JE; Szczech LA
Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
[TBL] [Abstract][Full Text] [Related]
6. Route of administration for erythropoiesis-stimulating agents: patient and nursing considerations.
Holloway M
Nephrol Nurs J; 2007; 34(5):527-31. PubMed ID: 18041455
[TBL] [Abstract][Full Text] [Related]
7. Exploring dosing frequency and administration routes in the treatment of anaemia in CKD patients.
Portolés J; Krisper P; Choukroun G; de Francisco AL
Nephrol Dial Transplant; 2005 Sep; 20 Suppl 8():viii13-17. PubMed ID: 16079324
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis.
Moist LM; Muirhead N; Wazny LD; Gallo KL; Heidenheim AP; House AA
Ann Pharmacother; 2006 Feb; 40(2):198-203. PubMed ID: 16449549
[TBL] [Abstract][Full Text] [Related]
9. Once weekly treatment with epoetin-beta.
Locatelli F
Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi26-30. PubMed ID: 15958823
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin and renal failure.
Macdougall IC
Curr Hematol Rep; 2003 Nov; 2(6):459-64. PubMed ID: 14561389
[TBL] [Abstract][Full Text] [Related]
11. Importance of biologic follow-ons: experience with EPO.
Casadevall N; Rossert J
Best Pract Res Clin Haematol; 2005; 18(3):381-7. PubMed ID: 15792912
[TBL] [Abstract][Full Text] [Related]
12. Erythropoiesis-stimulating agents in renal medicine.
Locatelli F; Del Vecchio L
Oncologist; 2011; 16 Suppl 3():19-24. PubMed ID: 21930831
[TBL] [Abstract][Full Text] [Related]
13. Antibody-mediated pure red cell aplasia related with epoetin-beta pegol (C.E.R.A.) as an erythropoietic agent: case report of a dialysis patient.
Shingu Y; Nakata T; Sawai S; Tanaka H; Asai O; Tamagaki K; Nakatani K
BMC Nephrol; 2020 Jul; 21(1):275. PubMed ID: 32664894
[TBL] [Abstract][Full Text] [Related]
14. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
Singh AK
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?
Walker RG
Clin J Am Soc Nephrol; 2008 Jul; 3(4):935-7. PubMed ID: 18579671
[No Abstract] [Full Text] [Related]
16. [Management of anemia in chronic kidney disease].
López Gómez JM
Nefrologia; 2008; 28 Suppl 3():63-6. PubMed ID: 19018741
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietic stimulating agents.
Testa U
Expert Opin Emerg Drugs; 2010 Mar; 15(1):119-38. PubMed ID: 20158404
[TBL] [Abstract][Full Text] [Related]
18. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA).
Krapf R; Hulter HN
Clin J Am Soc Nephrol; 2009 Feb; 4(2):470-80. PubMed ID: 19218474
[TBL] [Abstract][Full Text] [Related]
19. Pure red cell aplasia induced by erythropoiesis-stimulating agents.
Pollock C; Johnson DW; Hörl WH; Rossert J; Casadevall N; Schellekens H; Delage R; De Francisco A; Macdougall I; Thorpe R; Toffelmire E
Clin J Am Soc Nephrol; 2008 Jan; 3(1):193-9. PubMed ID: 18178785
[TBL] [Abstract][Full Text] [Related]
20. [Direct medical cost of erythropoiesis-stimulating agents in anaemia treatment of chronic renal failure patient: a literature review].
Ranchon F; Hédoux S; Laville M; Fouque D; Decullier E; Chapuis F; Huot L
Nephrol Ther; 2010 Apr; 6(2):97-104. PubMed ID: 20097148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
